A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

Dean M. Wingerchuk, E. E. Benarroch, P. C. O'Brien, B. M. Keegan, C. F. Lucchinetti, J. H. Noseworthy, B. G. Weinshenker, M. Rodriguez

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

Original languageEnglish (US)
Pages (from-to)1267-1269
Number of pages3
JournalNeurology
Volume64
Issue number7
DOIs
StatePublished - Apr 12 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this